Ignite Creation Date:
2024-10-26 @ 3:34 PM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06502522
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-09
Brief Title:
Effects of Whole-body Electrostimulation on Patients With Chronic Kidney Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effects of Whole-body Electrostimulation on Kidney Function and Physical Capacity of Patients With Chronic Kidney Disease Randomized Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chronic kidney disease CKD consists of kidney damage with consequent progressive and irreversible loss of kidney function In the early stages of the disease a reduction in circulating levels of the α-klotho protein is already observed which is related to worsening renal function Therapeutic strategies that increase serum levels of α-klotho may be of great value in the treatment of CKD Electrical stimulation contributes to the reduction of reactive oxygen species DNA damage and improves the effectiveness rate of dialysis suggesting a systemic effect in patients with terminal CKD The objective of this study is to evaluate the effects of whole body electrical stimulation on renal function and physical capacity in patients with CKD not dependent on dialysis
Detailed Description:
Patients with stage III and IV chronic kidney disease will be randomized into two groups one group will receive whole-body electrical stimulation and the other group will be a control group it will only be evaluated and reevaluated at the same times as the intervention group The intervention group will perform the protocol three times a week for eight weeks The following assessments will be conducted pre- and post-intervention analysis of plasma content of soluble α-Klotho and creatinine to assess renal function measurement of interleukins and tumor necrosis factor by ELISA to analyze the inflammatory profile beta-endorphin measurement by ELISA to assess well-being creatine kinase dosage to assess muscle damage 10-repetition sit-to-stand test and quadriceps muscle dynamometry to assess lower limb muscle strength handgrip test with a dynamometer to assess upper limb strength six-minute walk test to assess functional capacity application of the EuroQoL-5D questionnaire for quality of life and the Pittsburgh scale to assess sleep quality
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None